210. Single Ventricle Clinical trials / Disease details
Clinical trials : 51 / Drugs : 53 - (DrugBank : 22) / Drug target genes : 32 - Drug target pathways : 67
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02080637 (ClinicalTrials.gov) | July 2015 | 21/2/2014 | Ambrisentan in Single Ventricle | Safety, Pharmacokinetics (PK) and Hemodynamic Effects of Ambrisentan in Single Ventricle Pediatric Patients | Hypoplastic Left Heart Syndrome;Hypoplastic Right-sided Heart Complex | Drug: Ambrisentan;Other: Placebo | Kevin Hill | NULL | Completed | 24 Months | 120 Months | All | 16 | Phase 2 | United States |
| 2 | NCT01971580 (ClinicalTrials.gov) | August 2012 | 23/10/2013 | The Effects of Ambrisentan on Exercise Capacity in Fontan Patients | The Effects of Ambrisentan on Exercise Capacity in Fontan Patients | Single Ventricle Fontan Palliation | Drug: Ambrisentan | Washington University School of Medicine | NULL | Completed | 18 Years | 50 Years | All | 28 | Phase 4 | United States |